Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)
|
February 17, 2017
Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells
Anke Loregger, Jessica K Nelson, Noam Zelcer
Journal of Lipid Research
|
June 5, 2013
The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation
Vincenzo Sorrentino, Jessica K Nelson, Elena Maspero, et al.
Atherosclerosis
|
November 15, 2020
Regulation of intestinal LDLR by the LXR-IDOL axis
Nienke M van Loon, Suzanne A E van Wouw, Roelof Ottenhoff, et al.
Plos One
|
February 24, 2017
Identification of the ER-resident E3 ubiquitin ligase RNF145 as a novel LXR-regulated gene
Emma C L Cook, Jessica K Nelson, Vincenzo Sorrentino, et al.
Nature Communications
|
April 7, 2021
Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12
Omar M Khan, Jorge Almagro, Jessica K Nelson, et al.
European Heart Journal
|
January 18, 2013
Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein
Vincenzo Sorrentino, Sigrid W Fouchier, Mohammad M Motazacker, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
June 23, 2012
Reduced hexokinase II impairs muscle function 2 wk after ischemia-reperfusion through increased cell necrosis and fibrosis
Kirsten M Smeele, Otto Eerbeek, Gert Schaart, et al.
Circulation Research
|
November 20, 2015
Identification of the (Pro)renin Receptor as a Novel Regulator of Low-Density Lipoprotein Metabolism
Xifeng Lu, Marcel E Meima, Jessica K Nelson, et al.
The Journal of Experimental Medicine
|
January 16, 2019
LUBAC determines chemotherapy resistance in squamous cell lung cancer
E Josue Ruiz, Markus E Diefenbacher, Jessica K Nelson, et al.
Nature Communications
|
April 20, 2022
USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer
Jessica K Nelson, May Zaw Thin, Theodore Evan, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Methods in Molecular Biology (Clifton, N.J.)
|
February 17, 2017
Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells
Anke Loregger, Jessica K Nelson, Noam Zelcer
Journal of Lipid Research
|
June 5, 2013
The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation
Vincenzo Sorrentino, Jessica K Nelson, Elena Maspero, et al.
Atherosclerosis
|
November 15, 2020
Regulation of intestinal LDLR by the LXR-IDOL axis
Nienke M van Loon, Suzanne A E van Wouw, Roelof Ottenhoff, et al.
Plos One
|
February 24, 2017
Identification of the ER-resident E3 ubiquitin ligase RNF145 as a novel LXR-regulated gene
Emma C L Cook, Jessica K Nelson, Vincenzo Sorrentino, et al.
Nature Communications
|
April 7, 2021
Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12
Omar M Khan, Jorge Almagro, Jessica K Nelson, et al.
European Heart Journal
|
January 18, 2013
Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein
Vincenzo Sorrentino, Sigrid W Fouchier, Mohammad M Motazacker, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
June 23, 2012
Reduced hexokinase II impairs muscle function 2 wk after ischemia-reperfusion through increased cell necrosis and fibrosis
Kirsten M Smeele, Otto Eerbeek, Gert Schaart, et al.
Circulation Research
|
November 20, 2015
Identification of the (Pro)renin Receptor as a Novel Regulator of Low-Density Lipoprotein Metabolism
Xifeng Lu, Marcel E Meima, Jessica K Nelson, et al.
The Journal of Experimental Medicine
|
January 16, 2019
LUBAC determines chemotherapy resistance in squamous cell lung cancer
E Josue Ruiz, Markus E Diefenbacher, Jessica K Nelson, et al.
Nature Communications
|
April 20, 2022
USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer
Jessica K Nelson, May Zaw Thin, Theodore Evan, et al.
Page
of 2